Thelansis

Refractory Angina (RA) Market Outlook Thelansis’s “Refractory Angina (RA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Angina (RA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the greatest impact on the market’s trajector...

  Refractory Angina (RA) Market Outlook Thelansis’s “Refractory Angina (RA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Refractory Angina (RA) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Refractory Angina (RA) Overview Refractory angina (RA) is typically characterized as a persistent condition lasting at least three months, marked by angina in the presence of coronary artery disease (CAD) that remains unresponsive to a combination of optimal medical treatment, angioplasty, or bypass surgery. It is also confirmed that reversible myocardial ischemia is the underlying cause of the symptoms. Due to the complexity of CAD and...

 Refractory angina (RA) is typically characterized as a persistent condition lasting at least three months, marked by angina in the presence of coronary artery disease (CAD) that remains unresponsive to a combination of optimal medical treatment, angioplasty, or bypass surgery. It is also confirmed that reversible myocardial ischemia is the underlying cause of the symptoms. Due to the complexity of CAD and relevant comorbidities, surgical or percutaneous coronary revascularization is not deemed a viable option for these patients. ·        According to Thelansis disease modeling, the estimated incidence of RA is approximately 8% to 15% among patients who undergo cardiac catheterization. ·        The annual number of newly diagnosed RA patients in the United States is approximately 87,000. The estimated annual incidence in Europe ranges between approximately 38,000 and 57,400 new cases.   Thelansis’s “Refractory...